- Home
- BCTX vs ALLR Comparison
BCTX vs ALLR Comparison
Compare BCTX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- ALLR
- Stock Information
- Founded
- BCTX 2014
- ALLR 2004
- Country
- BCTX Canada
- ALLR United States
- Employees
- BCTX N/A
- ALLR N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- ALLR Health Care
- Exchange
- BCTX Nasdaq
- ALLR Nasdaq
- Market Cap
- BCTX 18.5M
- ALLR 20.2M
- IPO Year
- BCTX N/A
- ALLR N/A
- Fundamental
- Price
- BCTX $8.20
- ALLR $1.05
- Analyst Decision
- BCTX Strong Buy
- ALLR Strong Buy
- Analyst Count
- BCTX 1
- ALLR 1
- Target Price
- BCTX $40.00
- ALLR $9.25
- AVG Volume (30 Days)
- BCTX 45.4K
- ALLR 231.1K
- Earning Date
- BCTX 12-15-2025
- ALLR 11-14-2025
- Dividend Yield
- BCTX N/A
- ALLR N/A
- EPS Growth
- BCTX N/A
- ALLR N/A
- EPS
- BCTX N/A
- ALLR N/A
- Revenue
- BCTX N/A
- ALLR N/A
- Revenue This Year
- BCTX N/A
- ALLR N/A
- Revenue Next Year
- BCTX N/A
- ALLR N/A
- P/E Ratio
- BCTX N/A
- ALLR N/A
- Revenue Growth
- BCTX N/A
- ALLR N/A
- 52 Week Low
- BCTX $6.00
- ALLR $0.61
- 52 Week High
- BCTX $190.50
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- BCTX 36.92
- ALLR 34.79
- Support Level
- BCTX $6.93
- ALLR $0.99
- Resistance Level
- BCTX $11.54
- ALLR $1.17
- Average True Range (ATR)
- BCTX 0.78
- ALLR 0.10
- MACD
- BCTX -0.39
- ALLR -0.01
- Stochastic Oscillator
- BCTX 22.77
- ALLR 13.63
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.